Crispr Therapeutics shares tumble after significant earnings miss
ST. LOUIS - Bunge Global SA (NYSE:BG), a global agribusiness with a market capitalization of $16 billion and annual revenue exceeding $51 billion, announced Thursday that its wholly owned finance subsidiary, Bunge Limited Finance Corp., has priced a public offering of $1.3 billion in senior unsecured notes.
The offering consists of two equal tranches: $650 million of 4.550% Senior Notes due 2030 and $650 million of 5.150% Senior Notes due 2035. Bunge Global SA will fully and unconditionally guarantee these notes on a senior unsecured basis.
The transaction is expected to close on August 4, 2025, subject to customary closing conditions, according to the company’s press release statement.
Bunge indicated that proceeds from the offering will be used for general corporate purposes, which may include debt repayment and refinancing, working capital, capital expenditures, stock repurchases, and investments in subsidiaries.
Several financial institutions are serving as joint book-running managers for the offering, including Citigroup Global Markets Inc., Deutsche Bank Securities Inc., and Mizuho Securities USA LLC for both tranches.
Bunge Global SA, headquartered in St. Louis with its registered office in Geneva, Switzerland, is an agribusiness solutions provider with approximately 37,000 employees worldwide. The company specializes in grain origination, storage, distribution, and oilseed processing and refining.
The offering is being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission.
In other recent news, Bunge Limited reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved earnings per share (EPS) of $1.31, surpassing analyst expectations of $1.14, which marked a 14.91% positive surprise. However, Bunge’s revenue was 9.17 billion dollars, falling short of the anticipated 12.46 billion dollars, resulting in a significant revenue miss of 26.4%. These results highlight a divergence between the company’s earnings and revenue performance. Despite the revenue shortfall, investors showed optimism, which was evident as the company’s stock rose in pre-market trading. The EPS beat and strategic developments seem to have contributed to this positive sentiment. No analyst upgrades or downgrades were reported in the recent period. These developments provide investors with important insights into Bunge’s current financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.